DYNE THERAPEUTICS INC. - COMMON STOCK

Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy

18 Jan 2022 08:00:01 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

05 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy

02 Dec 2021 08:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

04 Nov 2021 07:30:01 By Nasdaq GlobeNewswire

Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day

13 Oct 2021 07:45:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Presents New In Vivo Data for its Duchenne Muscular Dystrophy Program During Muscle Study Group Annual Scientific Meeting Demonstrating Robust and Durable Exon Skipping and Dystrophin Expression

01 Oct 2021 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Host Virtual Research and Development Day on Wednesday, October 13, 2021

28 Sep 2021 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Chardan’s Virtual 5th Annual Genetic Medicines Conference

27 Sep 2021 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Presents New In Vivo Data for its Myotonic Dystrophy Type 1 Candidate (DYNE-101) Demonstrating Robust Splicing Correction During World Muscle Society 2021 Virtual Congress

20 Sep 2021 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights

05 Aug 2021 07:30:01 By Nasdaq GlobeNewswire

Dyne Therapeutics Presents Preclinical Data from its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

25 Jun 2021 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Chief Scientific Officer Transition

02 Jun 2021 16:05:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Jefferies Virtual Healthcare Conference

26 May 2021 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Presents New Preclinical Data from its Myotonic Dystrophy Type 1 Program During American Society of Gene & Cell Therapy Annual Meeting Demonstrating Sustained Knockdown of Toxic Human Nuclear DMPK RNA

14 May 2021 07:00:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

06 May 2021 07:29:00 By Nasdaq GlobeNewswire

New Preclinical Data from Dyne Therapeutics’ Myotonic Dystrophy Type 1 Program to be Featured in Presentations During Upcoming American Society of Gene & Cell Therapy Annual Meeting

27 Apr 2021 16:35:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights

04 Mar 2021 07:35:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer

04 Mar 2021 07:25:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs

08 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Pricing of $168 Million Public Offering

20 Jan 2021 20:05:29 By Nasdaq GlobeNewswire